MAGE-C1 Inhibitors
MAGE-C1 inhibitors encompass a diverse group of chemical compounds that are designed to interfere with the function and activity of the MAGE-C1 protein. MAGE-C1, also known as MAGE-A3, belongs to the cancer/testis antigen family and is primarily associated with various malignancies. The development of MAGE-C1 inhibitors is aimed at unraveling the mechanisms by which this protein contributes to cancer progression and identifying possible strategies to disrupt its role in cellular processes.
These inhibitors can be categorized into several classes, including kinase inhibitors, signal transduction pathway disruptors, and epigenetic modifiers. Kinase inhibitors such as staurosporine target kinases that are involved in signaling pathways associated with MAGE-C1. By blocking these kinases, they indirectly affect MAGE-C1-related downstream events. Signal transduction pathway disruptors like U0126 and LY294002 inhibit specific pathways, such as MAPK and PI3K/AKT, which interact with MAGE-C1 signaling. These compounds interfere with the activation of signaling cascades and may indirectly impede the influence of MAGE-C1 on these pathways. Epigenetic modifiers like vorinostat function by altering histone acetylation patterns, which in turn can modulate gene expression linked to MAGE-C1 and its associated pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum kinase inhibitor. It inhibits kinases involved in signaling pathways associated with MAGE-C1, disrupting downstream signaling and potentially inhibiting MAGE-C1 function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an inhibitor of phosphoinositide 3-kinase (PI3K). By blocking PI3K, it disrupts the PI3K/AKT signaling pathway, which is often linked to cancer-related pathways, indirectly impacting MAGE-C1. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. mTOR is a key regulator of cell growth and proliferation. Inhibiting mTOR with rapamycin can disrupt cellular processes that MAGE-C1 may rely on, potentially inhibiting its function. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Vorinostat is an HDAC (histone deacetylase) inhibitor. It modifies histone acetylation patterns, affecting gene expression. Changes in gene expression can indirectly impact pathways and cellular processes associated with MAGE-C1, potentially inhibiting its function. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 inhibits NF-κB activation, which is linked to inflammation and cancer pathways. By blocking NF-κB, it can indirectly affect signaling pathways that interact with MAGE-C1, potentially leading to its inhibition. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $39.00 $59.00 $104.00 $206.00 | 8 | |
Geldanamycin targets HSP90, a chaperone protein that stabilizes various signaling molecules. Inhibiting HSP90 can disrupt the stability of proteins involved in MAGE-C1-related pathways, potentially inhibiting MAGE-C1 function. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib targets EGFR, which is involved in cell proliferation pathways. Inhibition of EGFR can indirectly interfere with downstream signaling processes associated with MAGE-C1, potentially inhibiting its function. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
DAPT blocks Notch signaling, which is linked to cancer. Inhibition of Notch signaling can indirectly interfere with pathways involving MAGE-C1, potentially leading to its inhibition. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib inhibits JAK/STAT pathways related to immunity. By inhibiting these pathways, it can indirectly affect cellular processes linked to MAGE-C1, potentially inhibiting its function. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 disrupts proteasome function, affecting protein degradation. Inhibition of proteasomes can lead to the accumulation of misfolded proteins and affect the stability of proteins involved in MAGE-C1-related pathways, potentially inhibiting MAGE-C1. | ||||||